Verastem Set to Rise on Promising Cancer Drug Pipeline
AI Prediction of Verastem, Inc. (VSTM)
Verastem Inc., a biopharmaceutical company, is poised for growth with its FDA-approved drug for KRAS-mutant low-grade serous ovarian cancer (LGSOC) and other promising candidates targeting RAS/MAPK pathway-driven cancers.
Verastem Inc. focuses on developing treatments for cancers driven by the RAS/MAPK signaling pathway. Its flagship product, AVMAPKI FAKZYNJA CO-PACK, recently received FDA approval for KRAS-mutant recurrent LGSOC, marking a significant milestone. The company's pipeline includes VS-7375, a KRAS G12D inhibitor, currently in early-stage trials. Upcoming catalysts, such as further clinical results and potential new drug approvals, could significantly impact the company's stock price in the near term. The recent FDA approval and promising pipeline position Verastem to capitalize on the growing demand for targeted cancer therapies.
VSTM Report Information
Prediction Date2026-03-06
Close @ Prediction$6.15
Mkt Cap466m
IPO DateN/a
AI-derived Information
Recent News for VSTM
- Apr 10, 7:00 am — Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Womens Cancers (Business Wire)
- Apr 2, 4:05 pm — Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
- Mar 17, 6:03 pm — Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 (Business Wire)
- Mar 17, 4:44 pm — Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers (Business Wire)
- Mar 5, 8:30 am — Verastem, Inc. Q4 2025 Earnings Call Summary (Moby)
- Mar 5, 12:03 am — Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... (GuruFocus.com)
- Mar 4, 8:48 pm — Verastem Q4 Earnings Call Highlights (MarketBeat)
- Mar 4, 5:10 pm — Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
- Mar 4, 4:20 pm — Verastem: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 4, 4:01 pm — Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
- Feb 18, 7:30 am — Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
- Feb 17, 12:00 pm — What Makes Verastem (VSTM) a New Buy Stock (Zacks)
NDAPR (News-Driven AI Prediction Revision) events for VSTM
-
Apr 10, 7:06 amRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason: Continued clinical progressRationale: Catalyst progress with sustained clinical benefits and safety profile.
-
Mar 17, 4:52 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: Catalyst progress.
-
Mar 9, 12:56 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: No new catalysts or significant changes affecting the original prediction were identified.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest